Palisade Bio Announces Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Covering PALI-2108, An Orally Administered PDE4 Inhibitor Prodrug For Ulcerative Colitis
Palisade Bio Announces Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Covering PALI-2108, An Orally Administered PDE4 Inhibitor Prodrug For Ulcerative Colitis
Palisade Bio宣佈，加拿大知識產權局發佈了涵蓋PALI-2108的專利通知，這是一種口服PDE4抑制劑前藥，用於治療潰瘍性結腸炎。
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure
PALI-2108口服給藥，定位於結腸，具有局部活性和低系統曝氣。
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end
公司預計在今年年底前開始PALI-2108治療UC的一期人類臨床研究。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。